PMID-sentid Pub_year Sent_text comp_official_name comp_offsetprotein_name organism prot_offset 33324084-8 2020 Moreover, DAS treatment resulted in the recovery of antioxidant enzymes, SOD and CAT, in BaP-exposed mice. Benzo(a)pyrene 89-92 catalase Mus musculus 81-84 21787717-5 2011 Furthermore, GAT markedly inhibited the BaP-induced increase of Cu/Zn-SOD, CAT, GPx and GST activities in the mouse liver. Benzo(a)pyrene 40-43 catalase Mus musculus 75-78 20851761-5 2010 BaP treatment (1) significantly lowered levels of vitamins A, C, and E and of glutathione; (2) reduced activities of superoxide dismutase, catalase, glutathione peroxidase, and glutathione S-transferases; and (3) significantly increased lipid peroxidation levels. Benzo(a)pyrene 0-3 catalase Mus musculus 139-147 19666105-0 2009 Overexpression of Cu/Zn-superoxide dismutase and/or catalase accelerates benzo(a)pyrene detoxification by upregulation of the aryl hydrocarbon receptor in mouse endothelial cells. Benzo(a)pyrene 73-87 catalase Mus musculus 52-60 19666105-1 2009 A reduction in endogenously generated reactive oxygen species in vivo delays benzo(a)pyrene (BaP)-accelerated atherosclerosis, as revealed in hypercholesterolemic mice overexpressing Cu/Zn-superoxide dismutase (SOD) and/or catalase. Benzo(a)pyrene 77-91 catalase Mus musculus 223-231 19666105-1 2009 A reduction in endogenously generated reactive oxygen species in vivo delays benzo(a)pyrene (BaP)-accelerated atherosclerosis, as revealed in hypercholesterolemic mice overexpressing Cu/Zn-superoxide dismutase (SOD) and/or catalase. Benzo(a)pyrene 93-96 catalase Mus musculus 223-231 19666105-2 2009 To understand the molecular events involved in this protective action, we studied the effects of Cu/Zn-SOD and/or catalase overexpression on BaP detoxification and on aryl hydrocarbon receptor (AhR) expression and its target gene expression in mouse aortic endothelial cells (MAECs). Benzo(a)pyrene 141-144 catalase Mus musculus 114-122 19666105-4 2009 After BaP exposure, the amount of AhR binding to the cytochrome P450 (CYP) 1A1 promoter was significantly greater, and the concentrations of BaP reactive intermediates were significantly less in MAECs overexpressing Cu/Zn-SOD and/or catalase than in wild-type cells. Benzo(a)pyrene 6-9 catalase Mus musculus 233-241 19666105-6 2009 Moreover, knockdown of AhR with RNA interference diminished the Cu/Zn-SOD and catalase enhancement of CYP1A1 expression, GST activity, and BaP detoxification. Benzo(a)pyrene 139-142 catalase Mus musculus 78-86 17649736-12 2007 Benz(a)pyrene boosted blood serum MDA by 190%, catalase - by 267% and 116% in tumor tissue as compared with untreated controls. Benzo(a)pyrene 0-13 catalase Mus musculus 47-55 27607467-0 2016 Overexpression of Catalase Enhances Benzo(a)pyrene Detoxification in Endothelial Microsomes. Benzo(a)pyrene 36-50 catalase Mus musculus 18-26 27607467-1 2016 UNLABELLED: We previously reported that overexpression of catalase upregulated xenobiotic- metabolizing enzyme (XME) expression and diminished benzo(a)pyrene (BaP) intermediate accumulation in mouse aortic endothelial cells (MAECs). Benzo(a)pyrene 143-157 catalase Mus musculus 58-66 17310841-7 2006 The activity of catalase in the serum of BP-induced tumor-bearing mice was increased by 12.1% as compared to the intact control mice (p < 0.01) and was unchanged in the tumor tissue. Benzo(a)pyrene 41-43 catalase Mus musculus 16-24 17310841-8 2006 Treatment with melatonin at the dose of 2 mg/l significantly decreased activity of catalase in the serum (by 31.7%, p < 0.01) and in the tumor tissue (by 2.6 times, p < 0.01) as compared to the animals treated with BP alone. Benzo(a)pyrene 221-223 catalase Mus musculus 83-91 34903147-7 2022 The S. purpurea L extract increased CAT activity and GSH levels accompanied by a decrease in MDA levels after treatment with B(a)P and CP. Benzo(a)pyrene 125-130 catalase Mus musculus 36-39